2,965 results on '"Poewe, Werner"'
Search Results
2. Neuropathological spectrum of anti-IgLON5 disease and stages of brainstem tau pathology: updated neuropathological research criteria of the disease-related tauopathy
- Author
-
Gelpi, Ellen, Reinecke, Raphael, Gaig, Carles, Iranzo, Alex, Sabater, Lidia, Molina-Porcel, Laura, Aldecoa, Iban, Endmayr, Verena, Högl, Birgit, Schmutzhard, Erich, Poewe, Werner, Pfausler, Bettina, Popovic, Mara, Pretnar-Oblak, Janja, Leypoldt, Frank, Matschke, Jakob, Glatzel, Markus, Erro, Elena Maria, Jerico, Ivonne, Caballero, Maria Cristina, Zelaya, Maria Victoria, Mariotto, Sara, Heidbreder, Anna, Kalev, Ognian, Weis, Serge, Macher, Stefan, Berger-Sieczkowski, Evelyn, Ferrari, Julia, Reisinger, Christoph, Klupp, Nikolaus, Tienari, Pentti, Rautila, Osma, Niemelä, Marja, Yilmazer-Hanke, Deniz, Guasp, Mar, Bloem, Bas, Van Gaalen, Judith, Kusters, Benno, Titulaer, Maarten, Fransen, Nina L., Santamaria, Joan, Dawson, Thimoty, Holton, Janice L., Ling, Helen, Revesz, Tamas, Myllykangas, Liisa, Budka, Herbert, Kovacs, Gabor G., Lewerenz, Jan, Dalmau, Josep, Graus, Francesc, Koneczny, Inga, and Höftberger, Romana
- Published
- 2024
- Full Text
- View/download PDF
3. Long-term safety and efficacy of open-label nabilone on sleep and pain in Parkinson´s Disease
- Author
-
Peball, Marina, Heim, Beatrice, Carbone, Federico, Schorr, Oliver, Werkmann, Mario, Ellmerer, Philipp, Marini, Kathrin, Krismer, Florian, Knaus, Hans-Günther, Poewe, Werner, Djamshidian, Atbin, and Seppi, Klaus
- Published
- 2024
- Full Text
- View/download PDF
4. Sex-related differences in the clinical presentation of multiple system atrophy
- Author
-
Leys, Fabian, Eschlböck, Sabine, Campese, Nicole, Mahlknecht, Philipp, Peball, Marina, Goebel, Georg, Sidoroff, Victoria, Krismer, Florian, Granata, Roberta, Kiechl, Stefan, Poewe, Werner, Seppi, Klaus, Wenning, Gregor K., and Fanciulli, Alessandra
- Published
- 2024
- Full Text
- View/download PDF
5. The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy
- Author
-
Wenning, Gregor K, Stankovic, Iva, Vignatelli, Luca, Fanciulli, Alessandra, Calandra‐Buonaura, Giovanna, Seppi, Klaus, Palma, Jose‐Alberto, Meissner, Wassilios G, Krismer, Florian, Berg, Daniela, Cortelli, Pietro, Freeman, Roy, Halliday, Glenda, Höglinger, Günter, Lang, Anthony, Ling, Helen, Litvan, Irene, Low, Phillip, Miki, Yasuo, Panicker, Jalesh, Pellecchia, Maria Teresa, Quinn, Niall, Sakakibara, Ryuji, Stamelou, Maria, Tolosa, Eduardo, Tsuji, Shoji, Warner, Tom, Poewe, Werner, and Kaufmann, Horacio
- Subjects
Neurosciences ,Rare Diseases ,Prevention ,Brain Disorders ,4.1 Discovery and preclinical testing of markers and technologies ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Brain ,Consensus ,Humans ,Magnetic Resonance Imaging ,Multiple System Atrophy ,Prospective Studies ,multiple system atrophy ,diagnostic criteria ,diagnosis ,Clinical Sciences ,Human Movement and Sports Sciences ,Neurology & Neurosurgery - Abstract
BackgroundThe second consensus criteria for the diagnosis of multiple system atrophy (MSA) are widely recognized as the reference standard for clinical research, but lack sensitivity to diagnose the disease at early stages.ObjectiveTo develop novel Movement Disorder Society (MDS) criteria for MSA diagnosis using an evidence-based and consensus-based methodology.MethodsWe identified shortcomings of the second consensus criteria for MSA diagnosis and conducted a systematic literature review to answer predefined questions on clinical presentation and diagnostic tools relevant for MSA diagnosis. The criteria were developed and later optimized using two Delphi rounds within the MSA Criteria Revision Task Force, a survey for MDS membership, and a virtual Consensus Conference.ResultsThe criteria for neuropathologically established MSA remain unchanged. For a clinical MSA diagnosis a new category of clinically established MSA is introduced, aiming for maximum specificity with acceptable sensitivity. A category of clinically probable MSA is defined to enhance sensitivity while maintaining specificity. A research category of possible prodromal MSA is designed to capture patients in the earliest stages when symptoms and signs are present, but do not meet the threshold for clinically established or clinically probable MSA. Brain magnetic resonance imaging markers suggestive of MSA are required for the diagnosis of clinically established MSA. The number of research biomarkers that support all clinical diagnostic categories will likely grow.ConclusionsThis set of MDS MSA diagnostic criteria aims at improving the diagnostic accuracy, particularly in early disease stages. It requires validation in a prospective clinical and a clinicopathological study. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Published
- 2022
6. Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial
- Author
-
Afshari, Mitra, Amelin, Alexander, Arkadir, David, Badarny, Samih, Balaguer Martinez, Ernest, Bogucki, Andrzej, Boyd, James, Buyan Dent, Laura, Carroll, Camille, Chaudhuri, Kallol Ray, Cooney, Jeffrey, Corbillé, Anne-Gaëlle, Danaila, Teodor, De Pandis, Maria Francesca, Dethy, Sophie, Dhall, Rohit, Djaldetti, Ruth, Durif, Franck, Flitman, Stephen, Freire Alvarez, Eric, Goudreau, John, Grandas Perez, Francisco, Gurevich, Tanya, Isa, Arnaldo, Juncos, Jorge L, Kanchana, Sulada, Klodowska-Duda, Gabriela, Koziorowski, Dariusz, Kulisevsky Bojarski, Jaime, Lopez Lozano, Juan, Luo, Lan, Lytvynenko, Nataliya, Marconi, Roberto, Marques, Ana-Raquel, Martinez Castrillo, Juan Carlos, Martinez Torres, Irene, Mentreddi, Aashoo, Mir Rivera, Pablo, Moskovko, Sergii, Neryanova, Yuliya, Onofrj, Marco, Ostrem, Jill, Pacchetti, Claudio, Pavese, Nicola, Pellicano, Clelia, Revuelta, Gonzalo, Rodrigues, Ana Margarida, Rodriguez, Ramon, Rudzinska, Monika, Sarwar, Nighat, Schwartzbard, Julie, Scorr, Laura, Slevin, John, Slobodin, Tatyana, Spalletta, Gianfranco, Tagliati, Michele, Tai, Yen, Tessitore, Alessandro, Valkovic, Peter, Verhagen, Leo, Vostrikova, Elena, Yahalom, Gilad, Zalyalova, Zuleykha, Zarubova, Katerina, Zhukova, Irina, Espay, Alberto J, Stocchi, Fabrizio, Pahwa, Rajesh, Albanese, Alberto, Ellenbogen, Aaron, Ferreira, Joaquim J, Giladi, Nir, Hassin-Baer, Sharon, Hernandez-Vara, Jorge, Isaacson, Stuart H, Kieburtz, Karl, LeWitt, Peter A, Lopez-Manzanares, Lydia, Olanow, C Warren, Poewe, Werner, Sarva, Harini, Yardeni, Tami, Adar, Liat, Salin, Laurence, Lopes, Nelson, Sasson, Nissim, Case, Ryan, and Rascol, Olivier
- Published
- 2024
- Full Text
- View/download PDF
7. Cognitive dysfunction in de novo Parkinson disease: Remitting vs. progressive cognitive impairment
- Author
-
Kawabata, Kazuya, Djamshidian, Atbin, Bagarinao, Epifanio, Weintraub, Daniel, Seppi, Klaus, and Poewe, Werner
- Published
- 2024
- Full Text
- View/download PDF
8. A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria
- Author
-
Höglinger, Günter U, Adler, Charles H, Berg, Daniela, Klein, Christine, Outeiro, Tiago F, Poewe, Werner, Postuma, Ronald, Stoessl, A Jon, and Lang, Anthony E
- Published
- 2024
- Full Text
- View/download PDF
9. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data
- Author
-
Pagano, Gennaro, Boess, Frank G, Taylor, Kirsten I, Ricci, Benedicte, Mollenhauer, Brit, Poewe, Werner, Boulay, Anne, Anzures-Cabrera, Judith, Vogt, Annamarie, Marchesi, Maddalena, Post, Anke, Nikolcheva, Tania, Kinney, Gene G, Zago, Wagner M, Ness, Daniel K, Svoboda, Hanno, Britschgi, Markus, Ostrowitzki, Susanne, Simuni, Tanya, Marek, Kenneth, Koller, Martin, Sevigny, Jeff, Doody, Rachelle, Fontoura, Paulo, Umbricht, Daniel, Bonni, Azad, Investigators, PASADENA, Group, Prasinezumab Study, Altendorf, Claudia, Anandan, Chareyna, Andrews, Giulia, Ansquer, Solène, Arrouasse, Raphaele, Aslam, Sana, Azulay, Jean-Philippe, Baker, Jeanette, Martinez, Ernest Balaguer, Barbu, Shadi, Bardram, Kara, Bega, Danny, Marco, Helena Bejr-Kasem, Benatru, Isabelle, Benchetrit, Eve, Bernhard, Felix, Besharat, Amir, Bette, Sagari, Bichon, Amelie, Billnitzer, Andrew, Blondeau, Sophie, Boraud, Thomas, Borngräber, Freiderike, Boyd, James, Brockmann, Kathrin, Brodsky, Matthew, Brown, Ethan, Bruecke, Christof, Calvas, Fabienne, Canelo, Monica, Carbone, Federico, Carroll, Claire, Fernandez, Laura Casado, Cassé-Perrot, Catherine, Castrioto, Anna, Catala, Helene, Chan, Justine, Cheriet, Samia, Ciabarra, Anthony, Classen, Joseph, Coleman, Juliana, Coleman, Robert, Compta, Yaroslau, Corbillé, Anne-Gaëlle, Corvol, Jean-Christophe, Cosgaya, Mariana, Dahodwala, Nabila, Damier, Philippe, David, Elodie, Davis, Thomas, Dean, Marissa, Debilly, Berengere, DeGiorgio, Janell, Deik, Andres, Delaby, Laure, Delfini, Marie-Helene, Derkinderen, Pascal, Derost, Philipp, de Toledo, Maria, Deuel, Lisa, Diaz-Hernandez, Ann Marie, Dietiker, Cameron, Dimenshteyn, Karina, Dotor, Julio, Durif, Franck, Ebentheuer, Jens, Eggert, Karla Maria, Madueño, Sara Eichau, Eickhoff, Claudia, Ellenbogen, Aaron, Ellmerer, Philipp, and Vazquez, Ines Esparragosa
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Neurodegenerative ,Parkinson's Disease ,Clinical Research ,Neurosciences ,Aging ,Clinical Trials and Supportive Activities ,Brain Disorders ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Neurological ,PASADENA Investigators ,Prasinezumab Study Group ,MDS-UPDRS = Movement Disorder Society—Unified Parkinson's Disease Rating Scale ,Parkinson's disease ,Phase II clinical trial ,alpha-synuclein ,disease modification treatments ,disease progression ,monoclonal antibodies ,prasinezumab ,Psychology ,Clinical sciences ,Biological psychology - Abstract
Background: Currently available treatments for Parkinson's disease (PD) do not slow clinical progression nor target alpha-synuclein, a key protein associated with the disease. Objective: The study objective was to evaluate the efficacy and safety of prasinezumab, a humanized monoclonal antibody that binds aggregated alpha-synuclein, in individuals with early PD. Methods: The PASADENA study is a multicenter, randomized, double-blind, placebo-controlled treatment study. Individuals with early PD, recruited across the US and Europe, received monthly intravenous doses of prasinezumab (1,500 or 4,500 mg) or placebo for a 52-week period (Part 1), followed by a 52-week extension (Part 2) in which all participants received active treatment. Key inclusion criteria were: aged 40-80 years; Hoehn & Yahr (H&Y) Stage I or II; time from diagnosis ≤2 years; having bradykinesia plus one other cardinal sign of PD (e.g., resting tremor, rigidity); DAT-SPECT imaging consistent with PD; and either treatment naïve or on a stable monoamine oxidase B (MAO-B) inhibitor dose. Study design assumptions for sample size and study duration were built using a patient cohort from the Parkinson's Progression Marker Initiative (PPMI). In this report, baseline characteristics are compared between the treatment-naïve and MAO-B inhibitor-treated PASADENA cohorts and between the PASADENA and PPMI populations. Results: Of the 443 patients screened, 316 were enrolled into the PASADENA study between June 2017 and November 2018, with an average age of 59.9 years and 67.4% being male. Mean time from diagnosis at baseline was 10.11 months, with 75.3% in H&Y Stage II. Baseline motor and non-motor symptoms (assessed using Movement Disorder Society-Unified Parkinson's Disease Rating Scale [MDS-UPDRS]) were similar in severity between the MAO-B inhibitor-treated and treatment-naïve PASADENA cohorts (MDS-UPDRS sum of Parts I + II + III [standard deviation (SD)]; 30.21 [11.96], 32.10 [13.20], respectively). The overall PASADENA population (63.6% treatment naïve and 36.4% on MAO-B inhibitor) showed a similar severity in MDS-UPDRS scores (e.g., MDS-UPDRS sum of Parts I + II + III [SD]; 31.41 [12.78], 32.63 [13.04], respectively) to the PPMI cohort (all treatment naïve). Conclusions: The PASADENA study population is suitable to investigate the potential of prasinezumab to slow disease progression in individuals with early PD. Trial Registration: NCT03100149.
- Published
- 2021
10. Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients
- Author
-
Alcalay, Roy N, Wolf, Pavlina, Chiang, Ming Sum Ruby, Helesicova, Karolina, Zhang, Xiaokui Kate, Merchant, Kalpana, Hutten, Samantha J, Scherzer, Clemens, Caspell‐Garcia, Chelsea, Blauwendraat, Cornelis, Foroud, Tatiana, Nudelman, Kelly, Gan‐Or, Ziv, Simuni, Tanya, Chahine, Lana M, Levy, Oren, Zheng, Dandi, Li, Sardi, Sergio Pablo, Marek, Kenneth, Siderowf, Andrew, Seibyl, John, Coffey, Christopher, Tanner, Caroline, Tosun‐Turgut, Duygu, Shaw, Leslie M, Trojanowski, John Q, Singleton, Andrew, Kieburtz, Karl, Toga, Arthur, Mollenhauer, Brit, Galasko, Douglas, Poewe, Werner, Poston, Kathleen, Bressman, Susan, Reimer, Alyssa, Arnedo, Vanessa, Clark, Adrienne, Frasier, Mark, Kopil, Catherine, Chowdhury, Sohini, Sherer, Todd, Casaceli, Cynthia, Dorsey, Ray, Wilson, Renee, Mahes, Sugi, Salerno, Christina, Crawford, Karen, Casalin, Paola, Malferrari, Giulia, Weisz, Mali Gani, Orr‐Urtreger, Avi, Montine, Thomas, Baglieri, Chris, Christini, Amanda, Russell, David, Dahodwala, Nabila, Giladi, Nir, Factor, Stewart, Hogarth, Penelope, Standaert, David, Hauser, Robert, Jankovic, Joseph, Saint‐Hilaire, Marie, Richard, Irene, Shprecher, David, Fernandez, Hubert, Brockmann, Katrina, Rosenthal, Liana, Barone, Paolo, Espay, Alberto, Rowe, Dominic, Marder, Karen, Santiago, Anthony, Hu, Shu‐Ching, Isaacson, Stuart, Martinez, Javiar Ruiz, Tolosa, Eduardo, Tai, Yen, Politis, Marios, Smejdir, Debra, Rees, Linda, Williams, Karen, Kausar, Farah, Richardson, Whitney, Willeke, Diana, Peacock, Shawnees, Sommerfeld, Barbara, Freed, Alison, Wakeman, Katrina, Blair, Courtney, Guthrie, Stephanie, Harrell, Leigh, Hunter, Christine, Thomas, Cathi‐Ann, James, Raymond, Zimmerman, Grace, Brown, Victoria, and Mule, Jennifer
- Subjects
Clinical and Health Psychology ,Biomedical and Clinical Sciences ,Neurosciences ,Psychology ,Human Genome ,Parkinson's Disease ,Neurodegenerative ,Brain Disorders ,Aging ,Genetics ,Neurological ,Adult ,Dementia ,Disease Progression ,Female ,Genotype ,Glucosylceramidase ,Heterozygote ,Humans ,Male ,Mental Status and Dementia Tests ,Middle Aged ,Mutation ,Parkinson Disease ,Phenotype ,Parkinson’s Progression Markers Initiative ,Clinical Sciences ,Clinical and health psychology - Abstract
ObjectiveReduction in glucocerebrosidase (GCase; encoded by GBA) enzymatic activity has been linked to Parkinson's disease (PD). Here, we correlated GCase activity and PD phenotype in the Parkinson's Progression Markers Initiative (PPMI) cohort.MethodsWe measured GCase activity in dried blood spots from 1559 samples of participants in the inception PPMI cohort, collected in four annual visits (from baseline visit to Year-3). Participants (PD, n = 392; controls, n = 175) were fully sequenced for GBA variants by means of genome-wide genotyping arrays, whole-exome sequencing, whole-genome sequencing, Sanger sequencing, and RNA-sequencing.ResultsFifty-two PD participants (13.4%) and 13 (7.4%) controls carried a GBA variant. GBA status was strongly associated with GCase activity. Among noncarriers, GCase activity was similar between PD and controls. Among GBA p.E326K carriers (PD, n = 20; controls, n = 5), activity was significantly lower in PD carriers than control carriers (9.53 µmol/L/h vs. 11.68 µmol/L/h, P = 0.035). Glucocerebrosidase activity was moderately (r = 0.45) associated with white blood cell (WBC) count. Next, we divided the noncarriers with PD to tertiles based on WBC count-corrected enzymatic activity. Members of the lower tertile had higher MDS-Unified Parkinson's Disease Rating Scale motor score in the "off" medication examination at year-III exam. Longitudinal analyses demonstrated slight reduction of activity in samples collected earlier on in the study, likely because of longer storage time.InterpretationGCase activity is associated with GBA genotype, WBC count, and among p.E326K variant carriers, with PD status. Reduced activity may also be associated with worse phenotype but longer follow up is required to confirm this observation.
- Published
- 2020
11. The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent α-synuclein in experimental multiple system atrophy
- Author
-
Herrera-Vaquero, Marcos, Bouquio, Danielle, Kallab, Martin, Biggs, Karl, Nair, Gayatri, Ochoa, Jessica, Heras-Garvin, Antonio, Heid, Christian, Hadrovic, Inesa, Poewe, Werner, Wenning, Gregor K, Klärner, Frank-Gerrit, Schrader, Thomas, Bitan, Gal, and Stefanova, Nadia
- Subjects
Pharmacology and Pharmaceutical Sciences ,Biomedical and Clinical Sciences ,Neurodegenerative ,Brain Disorders ,Neurosciences ,Parkinson's Disease ,Development of treatments and therapeutic interventions ,5.1 Pharmaceuticals ,Neurological ,Animals ,Brain ,Bridged-Ring Compounds ,Cell Line ,Disease Models ,Animal ,Dopaminergic Neurons ,Humans ,Male ,Mice ,Multiple System Atrophy ,Neuroprotective Agents ,Organophosphates ,Protein Aggregation ,Pathological ,alpha-Synuclein ,Multiple system atrophy ,Mouse model ,Synucleinopathy ,Glial cytoplasmic inclusions ,Aggregation ,Oligomersation ,Seeding ,Neuropathology ,Biochemistry and Cell Biology ,Medical Biochemistry and Metabolomics ,Clinical Sciences ,Biochemistry & Molecular Biology ,Biochemistry and cell biology ,Medical biochemistry and metabolomics - Abstract
Multiple system atrophy (MSA) is a fatal, adult-onset neurodegenerative disorder that has no cure and very limited treatment options. MSA is characterized by deposition of fibrillar α-synuclein (α-syn) in glial cytoplasmic inclusions in oligodendrocytes. Similar to other synucleinopathies, α-syn self-assembly is thought to be a key pathologic event and a prominent target for disease modification in MSA. Molecular tweezers are broad-spectrum nanochaperones that prevent formation of toxic protein assemblies and enhance their clearance. The current lead compound, CLR01, has been shown to inhibit α-syn aggregation but has not yet been tested in the context of MSA. To fill this gap, here, we conducted a proof-of-concept study to assess the efficacy of CLR01 in remodeling MSA-like α-syn pathology in the PLP-α-syn mouse model of MSA. Six-month-old mice received intracerebroventricular CLR01 (0.3 or 1 mg/kg per day) or vehicle for 32 days. Open-field test revealed a significant, dose-dependent amelioration of an anxiety-like phenotype. Subsequently, immunohistochemical and biochemical analyses showed dose-dependent reduction of pathological and seeding-competent forms of α-syn, which correlated with the behavioral phenotype. CLR01 treatment also promoted dopaminergic neuron survival in the substantia nigra. To our knowledge, this is the first demonstration of an agent that reduces formation of putative high-molecular-weight oligomers and seeding-competent α-syn in a mouse model of MSA, supporting the view that these species are key to the neurodegenerative process and its cell-to-cell progression in MSA. Our study suggests that CLR01 is an attractive therapeutic candidate for disease modification in MSA and related synucleinopathies, supporting further preclinical development.
- Published
- 2019
12. Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial
- Author
-
Ferreira, Joaquim J., Poewe, Werner, Rascol, Olivier, Stocchi, Fabrizio, Antonini, Angelo, Moreira, Joana, Pereira, Ana, Rocha, José-Francisco, and Soares-da-Silva, Patrício
- Published
- 2022
- Full Text
- View/download PDF
13. Long‐Term Medication Profiles in Parkinson's Disease under Subthalamic Deep Brain Stimulation: A Controlled Study
- Author
-
Theyer, Christoph, primary, Beliveau, Vincent, additional, Krismer, Florian, additional, Peball, Marina, additional, Mair, Katherina, additional, Heim, Beatrice, additional, Djamshidian, Atbin, additional, Kiechl, Stefan, additional, Eisner, Wilhelm, additional, Eschlböck, Sabine, additional, Wenning, Gregor K., additional, Willeit, Peter, additional, Seppi, Klaus, additional, Poewe, Werner, additional, and Mahlknecht, Philipp, additional
- Published
- 2024
- Full Text
- View/download PDF
14. Undetected ophthalmological disorders in Parkinson’s disease
- Author
-
Borm, Carlijn D. J. M., Werkmann, Mario, de Graaf, Debbie, Visser, Femke, Hofer, Arno, Peball, Marina, Smilowska, Katarzyna, Putz, Diana, Seppi, Klaus, Poewe, Werner, Hoyng, Carel, Bloem, Bastiaan R., Theelen, Thomas, and de Vries, Nienke M.
- Published
- 2022
- Full Text
- View/download PDF
15. P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease
- Author
-
Hauser, Robert A., Giladi, Nir, Poewe, Werner, Brotchie, Jonathan, Friedman, Hadas, Oren, Sheila, and Litman, Pninit
- Published
- 2022
- Full Text
- View/download PDF
16. How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy.
- Author
-
Grimm, Max-Joseph, Respondek, Gesine, Stamelou, Maria, Arzberger, Thomas, Ferguson, Leslie, Gelpi, Ellen, Giese, Armin, Grossman, Murray, Irwin, David J, Pantelyat, Alexander, Rajput, Alex, Roeber, Sigrun, van Swieten, John C, Troakes, Claire, Antonini, Angelo, Bhatia, Kailash P, Colosimo, Carlo, van Eimeren, Thilo, Kassubek, Jan, Levin, Johannes, Meissner, Wassilios G, Nilsson, Christer, Oertel, Wolfgang H, Piot, Ines, Poewe, Werner, Wenning, Gregor K, Boxer, Adam, Golbe, Lawrence I, Josephs, Keith A, Litvan, Irene, Morris, Huw R, Whitwell, Jennifer L, Compta, Yaroslau, Corvol, Jean-Christophe, Lang, Anthony E, Rowe, James B, Höglinger, Günter U, and Movement Disorder Society-endorsed PSP Study Group
- Subjects
Movement Disorder Society-endorsed PSP Study Group ,Brain ,Humans ,Parkinsonian Disorders ,Supranuclear Palsy ,Progressive ,Ocular Motility Disorders ,Sensation Disorders ,Autopsy ,Retrospective Studies ,Cohort Studies ,Adult ,Aged ,Aged ,80 and over ,Middle Aged ,Societies ,Medical ,Female ,Male ,Postural Balance ,Cognitive Dysfunction ,autopsy ,diversity ,phenotype ,progressive supranuclear palsy ,Brain Disorders ,Pediatric ,Neurosciences ,Rare Diseases ,Clinical Research ,Perinatal Period - Conditions Originating in Perinatal Period ,4.2 Evaluation of markers and technologies ,Neurology & Neurosurgery ,Clinical Sciences ,Human Movement and Sports Sciences - Abstract
BackgroundThe Movement Disorder Society criteria for progressive supranuclear palsy define diagnostic allocations, stratified by certainty levels and clinical predominance types. We aimed to study the frequency of ambiguous multiple allocations and to develop rules to eliminate them.MethodsWe retrospectively collected standardized clinical data by chart review in a multicenter cohort of autopsy-confirmed patients with progressive supranuclear palsy, to classify them by diagnostic certainty level and predominance type and to identify multiple allocations.ResultsComprehensive data were available from 195 patients. More than one diagnostic allocation occurred in 157 patients (80.5%). On average, 5.4 allocations were possible per patient. We developed four rules for Multiple Allocations eXtinction (MAX). They reduced the number of patients with multiple allocations to 22 (11.3%), and the allocations per patient to 1.1.ConclusionsThe proposed MAX rules help to standardize the application of the Movement Disorder Society criteria for progressive supranuclear palsy. © 2019 International Parkinson and Movement Disorder Society.
- Published
- 2019
17. Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)
- Author
-
Prakash, Neha, Caspell-Garcia, Chelsea, Coffey, Christopher, Siderowf, Andrew, Tanner, Caroline M, Kieburtz, Karl, Mollenhauer, Brit, Galasko, Douglas, Merchant, Kalpana, Foroud, Tatiana, Chahine, Lana M, Weintraub, Daniel, Casaceli, Cindy, Dorsey, Ray, Wilson, Renee, Herzog, Margaret, Daegele, Nichole, Arnedo, Vanessa, Frasier, Mark, Sherer, Todd, Marek, Ken, Frank, Samuel, Jennings, Danna, Simuni, Tanya, Marek, Kenneth, Seibyl, John, Tanner, Caroline, Tosun-Turgut, Duygu, Shaw, Leslie, Trojanowski, John, Singleton, Andrew, Toga, Arthur, Poewe, Werner, Poston, Kathleen, Chowdhury, Sohini, Kopil, Catherine, Casaceli, Cynthia, Mahes, Sugi, Salerno, Christina, Crawford, Karen, Casalin, Paola, Malferrari, Giulia, Weisz, Mali Gani, Orr-Urtreger, Avi, Montine, Thomas, Russell, David, Dahodwala, Nabila, Giladi, Nir, Factor, Stewart, Hogarth, Penelope, Standaert, David, Hauser, Robert, Jankovic, Joseph, Saint-Hilaire, Marie, Richard, Irene, Shprecher, David, Fernandez, Hubert, Brockmann, Katrina, Rosenthal, Liana, Barone, Paolo, Espay, Alberto, Rowe, Dominic, Marder, Karen, Santiago, Anthony, Bressman, Susan, Hu, Shu-Ching, Isaacson, Stuart, Corvol, Jean-Christophe, Martinez, Javiar Ruiz, and Tolosa, Eduardo
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Parkinson's Disease ,Prevention ,Clinical Research ,Brain Disorders ,Neurodegenerative ,Aging ,Neurosciences ,Neurological ,Aged ,Biomarkers ,Cohort Studies ,Disease Progression ,Feasibility Studies ,Female ,Humans ,Longitudinal Studies ,Male ,Middle Aged ,Parkinson Disease ,Post-Dural Puncture Headache ,Spinal Puncture ,Tinnitus ,Parkinson's disease ,Lumbar puncture ,Safety ,Adverse events ,Parkinson's Progression Markers InitiativeSteering Committee ,Study Cores ,Site Investigators ,Coordinators ,Industry and Scientific Advisory Board ,Cognitive Sciences ,Neurology & Neurosurgery ,Clinical sciences ,Biological psychology - Abstract
ObjectiveTo determine the feasibility, safety and tolerability of lumbar punctures (LPs) in research participants with early Parkinson disease (PD), subjects without evidence of dopaminergic deficiency (SWEDDs) and healthy volunteers (HC).BackgroundCerebrospinal fluid (CSF) analysis is becoming an essential part of the biomarkers discovery effort in PD with still limited data on safety and feasibility of serial LPs in PD participants.Design/methodsParkinson's Progression Marker Initiative (PPMI) is a longitudinal observation study designed to identify PD progression biomarkers. All PPMI participants undergo LP at baseline, 6, 12 months and yearly thereafter. CSF collection is performed by a trained investigator using predominantly atraumatic needles. Adverse events (AEs) are monitored by phone one week after LP completion. We analyzed safety data from baseline LPs.ResultsPPMI enrolled 683 participants (423 PD/196 HC/64 SWEDDs) from 23 study sites. CSF was collected at baseline in 97.5% of participants, of whom 5.4% underwent collection under fluoroscopy. 23% participants reported any related AEs, 68% of all AE were mild while 5.6% were severe. The most common AEs were headaches (13%) and low back pain (6.5%) and both occurred more commonly in HC and SWEDDs compared to PD participants. Factors associated with higher incidence of AEs across the cohorts included female gender, younger age and use of traumatic needles with larger diameter. AEs largely did not impact compliance with the future LPs.ConclusionsLPs are safe and feasible in PD research participants. Specific LP techniques (needle type and gauge) may reduce the overall incidence of AEs.
- Published
- 2019
18. Characterization and diagnostic potential of R2* in early-stage progressive supranuclear palsy variants
- Author
-
Beliveau, Vincent, Müller, Christoph, Steiger, Ruth, Gizewski, Elke R., Poewe, Werner, Seppi, Klaus, and Scherfler, Christoph
- Published
- 2022
- Full Text
- View/download PDF
19. Cardiac sympathetic innervation in Parkinson’s disease versus multiple system atrophy
- Author
-
Eckhardt, Christine, Krismer, Florian, Donnemiller, Eveline, Eschlböck, Sabine, Fanciulli, Alessandra, Raccagni, Cecilia, Bösch, Sylvia, Mair, Katherina, Scherfler, Christoph, Djamshidian, Atbin, Uprimny, Christian, Metzler, Bernhard, Seppi, Klaus, Poewe, Werner, Kiechl, Stefan, Virgolini, Irene, and Wenning, Gregor K.
- Published
- 2022
- Full Text
- View/download PDF
20. Prodromal Parkinson's disease: hype or hope for disease-modification trials?
- Author
-
Mahlknecht, Philipp, Marini, Kathrin, Werkmann, Mario, Poewe, Werner, and Seppi, Klaus
- Published
- 2022
- Full Text
- View/download PDF
21. Multiple system atrophy
- Author
-
Poewe, Werner, Stankovic, Iva, Halliday, Glenda, Meissner, Wassilios G., Wenning, Gregor K., Pellecchia, Maria Teresa, Seppi, Klaus, Palma, Jose-Alberto, and Kaufmann, Horacio
- Published
- 2022
- Full Text
- View/download PDF
22. Pain in Multiple System Atrophy: A Community‐Based Survey.
- Author
-
Campese, Nicole, Göbel, Georg, Wanschitz, Julia, Schlager, Andreas, Caliò, Bianca, Leys, Fabian, Bower, Pam, Kellerman, Larry, Zamarian, Laura, Bannister, Kirsty, Chaudhuri, Kallol Ray, Schrag, Anette, Freeman, Roy, Kaufmann, Horacio, Granata, Roberta, Kiechl, Stefan, Poewe, Werner, Seppi, Klaus, Wenning, Gregor, and Fanciulli, Alessandra
- Abstract
Background: Pain is a frequent yet poorly characterized symptom of multiple system atrophy (MSA). Understanding the factors influencing pain and its burden is crucial for improving the symptomatic treatment and quality of life of MSA individuals. Objective: This study aimed at assessing the prevalence, characteristics, and current treatment strategies for pain in MSA. Methods: A community‐based, online survey was conducted from February to May 2023. Invitations were extended to MSA individuals and informal MSA caregivers through patient advocacies and social media. Results: We included 190 persons with MSA and 114 caregivers. Eighty‐seven percent of MSA individuals reported pain, which was more prevalent among women (odds ratio [OR]: 6.38 [95% confidence interval, CI: 1.27–32.08], P = 0.025) and low‐income groups (OR: 5.02 [95% CI: 1.32–19.08], P = 0.018). Neck and shoulders (58%), back (45%), and legs (45%) were mostly affected. In the neck and shoulders, pain was associated with MSA core features, like orthostatic intolerance (OR: 4.80 [95% CI: 1.92–12.02], P = 0.001) and antecollis (OR: 3.24 [95% CI: 1.54–6.82], P = 0.002). Seventy‐six percent of individuals experiencing pain received treatment, mostly nonsteroidal anti‐inflammatory drugs (47%), acetaminophen (39%), and opioids (28%). Only 53% of respondents reported at least partial satisfaction with their current pain management. Pain mostly impacted work, household activities, and hobbies of MSA individuals, and caregivers' social activities. Conclusions: Pain is more prevalent than previously reported in MSA and particularly affects women and low‐income groups. Despite its frequency, pain management remains suboptimal, highlighting an urgent therapeutic need, likely entailing an optimized management of MSA core motor and non‐motor features. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Movement disorder society criteria for clinically established early Parkinson's disease
- Author
-
Berg, Daniela, Adler, Charles H, Bloem, Bastiaan R, Chan, Piu, Gasser, Thomas, Goetz, Christopher G, Halliday, Glenda, Lang, Anthony E, Lewis, Simon, Li, Yuan, Liepelt‐Scarfone, Inga, Litvan, Irene, Marek, Kenneth, Maetzler, Corina, Mi, Taomian, Obeso, José, Oertel, Wolfgang, Olanow, C Warren, Poewe, Werner, Rios‐Romenets, Silvia, Schäffer, Eva, Seppi, Klaus, Heim, Beatrice, Slow, Elizabeth, Stern, Matthew, Bledsoe, Ian O, Deuschl, Günther, and Postuma, Ronald B
- Subjects
Neurodegenerative ,Neurosciences ,Brain Disorders ,Aging ,Prevention ,Parkinson's Disease ,4.1 Discovery and preclinical testing of markers and technologies ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Neurological ,Aged ,Female ,Humans ,International Cooperation ,Male ,Middle Aged ,Parkinson Disease ,Reproducibility of Results ,Sensitivity and Specificity ,Severity of Illness Index ,Societies ,Medical ,Parkinson's disease ,diagnosis ,criteria ,Clinical Sciences ,Human Movement and Sports Sciences ,Neurology & Neurosurgery - Abstract
BackgroundIn 2015, the International Parkinson and Movement Disorder Society published clinical diagnostic criteria for Parkinson's disease (PD). Although recent validation studies suggest high accuracy, one unmet need is for highly specific criteria for clinical trials in early/de novo PD.ObjectivesThe objective of this study was to generate and test a PD diagnostic criteria termed "clinically established early PD."MethodsWe modified the Movement Disorder Society criteria to increase specificity for early PD by removing all disease duration components and changing red flags to absolute exclusions. We then estimated the sensitivity/specificity of clinically established early PD criteria in patients with disease duration
- Published
- 2018
24. Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting
- Author
-
Walsh, Ryan R, Krismer, Florian, Galpern, Wendy R, Wenning, Gregor K, Low, Phillip A, Halliday, Glenda, Koroshetz, Walter J, Holton, Janice, Quinn, Niall P, Rascol, Olivier, Shaw, Leslie M, Eidelberg, David, Bower, Pam, Cummings, Jeffrey L, Abler, Victor, Biedenharn, Judy, Bitan, Gal, Brooks, David J, Brundin, Patrik, Fernandez, Hubert, Fortier, Philip, Freeman, Roy, Gasser, Thomas, Hewitt, Art, Höglinger, Günter U, Huentelman, Matt J, Jensen, Poul H, Jeromin, Andreas, Kang, Un Jung, Kaufmann, Horacio, Kellerman, Lawrence, Khurana, Vikram, Klockgether, Thomas, Kim, Woojin Scott, Langer, Carol, LeWitt, Peter, Masliah, Eliezer, Meissner, Wassilios, Melki, Ronald, Ostrowitzki, Susanne, Piantadosi, Steven, Poewe, Werner, Robertson, David, Roemer, Cyndi, Schenk, Dale, Schlossmacher, Michael, Schmahmann, Jeremy D, Seppi, Klaus, Shih, Lily, Siderowf, Andrew, Stebbins, Glenn T, Stefanova, Nadia, Tsuji, Shoji, Sutton, Sharon, and Zhang, Jing
- Subjects
Rare Diseases ,Humans ,Multiple System Atrophy ,Nevada ,Patient Advocacy ,Research Design ,Clinical Sciences ,Neurosciences ,Cognitive Sciences ,Neurology & Neurosurgery - Abstract
Multiple system atrophy (MSA) is a rare neurodegenerative disorder with substantial knowledge gaps despite recent gains in basic and clinical research. In order to make further advances, concerted international collaboration is vital. In 2014, an international meeting involving leaders in the field and MSA advocacy groups was convened in Las Vegas, Nevada, to identify critical research areas where consensus and progress was needed to improve understanding, diagnosis, and treatment of the disease. Eight topic areas were defined: pathogenesis, preclinical modeling, target identification, endophenotyping, clinical measures, imaging biomarkers, nonimaging biomarkers, treatments/trial designs, and patient advocacy. For each topic area, an expert served as a working group chair and each working group developed priority-ranked research recommendations with associated timelines and pathways to reach the intended goals. In this report, each groups' recommendations are provided.
- Published
- 2018
25. Amantadine in the treatment of Parkinson's disease and other movement disorders
- Author
-
Rascol, Olivier, Fabbri, Margherita, and Poewe, Werner
- Published
- 2021
- Full Text
- View/download PDF
26. Reductions in OFF Time with ND0612 for People with Parkinson’s Disease Experiencing Motor Fluctuations: Responder-analysis from an Open-label Study (P9-3.019)
- Author
-
Isaacson, Stuart, primary, Poewe, Werner, additional, and Lopes, Nelson, additional
- Published
- 2024
- Full Text
- View/download PDF
27. Biological Staging of the Parkinson’s Progression Markers Initiative (PPMI) Cohort Using the Research Neuronal α-synuclein Disease Integrated Staging System (NSD-ISS) (P11-3.009)
- Author
-
Tanner, Caroline, primary, Simuni, Tanya, additional, Chahine, Lana, additional, Poston, Kathleen, additional, Brumm, Michael, additional, Chowdry, Sohini, additional, Coffey, Christopher, additional, Concha-Marambio, Luis, additional, Dam, Tien, additional, DiBiaso, Peter, additional, Foroud, Tatiana, additional, Frasier, Mark, additional, Gochanour, Caroline, additional, Jennings, Danna, additional, Kieburtz, Karl, additional, Kopil, Catherine, additional, Merchant, Kalpana, additional, Mollenhauer, Brit, additional, Montine, Thomas, additional, Nudelman, Kelly, additional, Pagano, Gennaro, additional, Seibyl, John, additional, Sherer, Todd, additional, Singleton, Andrew, additional, Stephenson, Diane, additional, Stern, Matthew, additional, Soto, Claudio, additional, Tolosa, Eduardo, additional, Weintraub, Daniel, additional, Xiao, Yuge, additional, Siderowf, Andrew, additional, Poewe, Werner, additional, and Marek, Kenneth, additional
- Published
- 2024
- Full Text
- View/download PDF
28. Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial
- Author
-
Espay, Alberto J, primary, Stocchi, Fabrizio, additional, Pahwa, Rajesh, additional, Albanese, Alberto, additional, Ellenbogen, Aaron, additional, Ferreira, Joaquim J, additional, Giladi, Nir, additional, Gurevich, Tanya, additional, Hassin-Baer, Sharon, additional, Hernandez-Vara, Jorge, additional, Isaacson, Stuart H, additional, Kieburtz, Karl, additional, LeWitt, Peter A, additional, Lopez-Manzanares, Lydia, additional, Olanow, C Warren, additional, Poewe, Werner, additional, Sarva, Harini, additional, Yardeni, Tami, additional, Adar, Liat, additional, Salin, Laurence, additional, Lopes, Nelson, additional, Sasson, Nissim, additional, Case, Ryan, additional, Rascol, Olivier, additional, Afshari, Mitra, additional, Amelin, Alexander, additional, Arkadir, David, additional, Badarny, Samih, additional, Balaguer Martinez, Ernest, additional, Bogucki, Andrzej, additional, Boyd, James, additional, Buyan Dent, Laura, additional, Carroll, Camille, additional, Chaudhuri, Kallol Ray, additional, Cooney, Jeffrey, additional, Corbillé, Anne-Gaëlle, additional, Danaila, Teodor, additional, De Pandis, Maria Francesca, additional, Dethy, Sophie, additional, Dhall, Rohit, additional, Djaldetti, Ruth, additional, Durif, Franck, additional, Flitman, Stephen, additional, Freire Alvarez, Eric, additional, Goudreau, John, additional, Grandas Perez, Francisco, additional, Isa, Arnaldo, additional, Juncos, Jorge L, additional, Kanchana, Sulada, additional, Klodowska-Duda, Gabriela, additional, Koziorowski, Dariusz, additional, Kulisevsky Bojarski, Jaime, additional, Lopez Lozano, Juan, additional, Luo, Lan, additional, Lytvynenko, Nataliya, additional, Marconi, Roberto, additional, Marques, Ana-Raquel, additional, Martinez Castrillo, Juan Carlos, additional, Martinez Torres, Irene, additional, Mentreddi, Aashoo, additional, Mir Rivera, Pablo, additional, Moskovko, Sergii, additional, Neryanova, Yuliya, additional, Onofrj, Marco, additional, Ostrem, Jill, additional, Pacchetti, Claudio, additional, Pavese, Nicola, additional, Pellicano, Clelia, additional, Revuelta, Gonzalo, additional, Rodrigues, Ana Margarida, additional, Rodriguez, Ramon, additional, Rudzinska, Monika, additional, Sarwar, Nighat, additional, Schwartzbard, Julie, additional, Scorr, Laura, additional, Slevin, John, additional, Slobodin, Tatyana, additional, Spalletta, Gianfranco, additional, Tagliati, Michele, additional, Tai, Yen, additional, Tessitore, Alessandro, additional, Valkovic, Peter, additional, Verhagen, Leo, additional, Vostrikova, Elena, additional, Yahalom, Gilad, additional, Zalyalova, Zuleykha, additional, Zarubova, Katerina, additional, and Zhukova, Irina, additional
- Published
- 2024
- Full Text
- View/download PDF
29. Pharmacotherapy for Disease Modification in Early Parkinson’s Disease: How Early Should We Be?
- Author
-
Mahlknecht, Philipp, primary and Poewe, Werner, additional
- Published
- 2024
- Full Text
- View/download PDF
30. A Blinded Evaluation of Brain Morphometry for Differential Diagnosis of Atypical Parkinsonism
- Author
-
Kawabata, Kazuya, primary, Krismer, Florian, additional, Heim, Beatrice, additional, Hussl, Anna, additional, Mueller, Christoph, additional, Scherfler, Christoph, additional, Gizewski, Elke R., additional, Seppi, Klaus, additional, and Poewe, Werner, additional
- Published
- 2024
- Full Text
- View/download PDF
31. Challenges in the diagnosis of Parkinson's disease
- Author
-
Tolosa, Eduardo, Garrido, Alicia, Scholz, Sonja W, and Poewe, Werner
- Published
- 2021
- Full Text
- View/download PDF
32. Characterization and diagnostic potential of diffusion tractography in multiple system atrophy
- Author
-
Beliveau, Vincent, Krismer, Florian, Skalla, Elisabeth, Schocke, Michael M., Gizewski, Elke R., Wenning, Gregor K., Poewe, Werner, Seppi, Klaus, and Scherfler, Christoph
- Published
- 2021
- Full Text
- View/download PDF
33. Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study
- Author
-
Katzenschlager, Regina, Poewe, Werner, Rascol, Olivier, Trenkwalder, Claudia, Deuschl, Günther, Chaudhuri, K Ray, Henriksen, Tove, van Laar, Teus, Lockhart, Donna, Staines, Harry, and Lees, Andrew
- Published
- 2021
- Full Text
- View/download PDF
34. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.
- Author
-
Höglinger, Günter U, Respondek, Gesine, Stamelou, Maria, Kurz, Carolin, Josephs, Keith A, Lang, Anthony E, Mollenhauer, Brit, Müller, Ulrich, Nilsson, Christer, Whitwell, Jennifer L, Arzberger, Thomas, Englund, Elisabet, Gelpi, Ellen, Giese, Armin, Irwin, David J, Meissner, Wassilios G, Pantelyat, Alexander, Rajput, Alex, van Swieten, John C, Troakes, Claire, Antonini, Angelo, Bhatia, Kailash P, Bordelon, Yvette, Compta, Yaroslau, Corvol, Jean-Christophe, Colosimo, Carlo, Dickson, Dennis W, Dodel, Richard, Ferguson, Leslie, Grossman, Murray, Kassubek, Jan, Krismer, Florian, Levin, Johannes, Lorenzl, Stefan, Morris, Huw R, Nestor, Peter, Oertel, Wolfgang H, Poewe, Werner, Rabinovici, Gil, Rowe, James B, Schellenberg, Gerard D, Seppi, Klaus, van Eimeren, Thilo, Wenning, Gregor K, Boxer, Adam L, Golbe, Lawrence I, Litvan, Irene, and Movement Disorder Society-endorsed PSP Study Group
- Subjects
Movement Disorder Society-endorsed PSP Study Group ,Humans ,Supranuclear Palsy ,Progressive ,Societies ,Medical ,Practice Guidelines as Topic ,clinical diagnostic criteria ,consensus-based ,evidence-based ,progressive supranuclear palsy ,Brain Disorders ,Neurosciences ,Neurological ,Clinical Sciences ,Human Movement and Sports Sciences ,Neurology & Neurosurgery - Abstract
BackgroundPSP is a neuropathologically defined disease entity. Clinical diagnostic criteria, published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for PSP, have excellent specificity, but their sensitivity is limited for variant PSP syndromes with presentations other than Richardson's syndrome.ObjectiveWe aimed to provide an evidence- and consensus-based revision of the clinical diagnostic criteria for PSP.MethodsWe searched the PubMed, Cochrane, Medline, and PSYCInfo databases for articles published in English since 1996, using postmortem diagnosis or highly specific clinical criteria as the diagnostic standard. Second, we generated retrospective standardized clinical data from patients with autopsy-confirmed PSP and control diseases. On this basis, diagnostic criteria were drafted, optimized in two modified Delphi evaluations, submitted to structured discussions with consensus procedures during a 2-day meeting, and refined in three further Delphi rounds.ResultsDefined clinical, imaging, laboratory, and genetic findings serve as mandatory basic features, mandatory exclusion criteria, or context-dependent exclusion criteria. We identified four functional domains (ocular motor dysfunction, postural instability, akinesia, and cognitive dysfunction) as clinical predictors of PSP. Within each of these domains, we propose three clinical features that contribute different levels of diagnostic certainty. Specific combinations of these features define the diagnostic criteria, stratified by three degrees of diagnostic certainty (probable PSP, possible PSP, and suggestive of PSP). Clinical clues and imaging findings represent supportive features.ConclusionsHere, we present new criteria aimed to optimize early, sensitive, and specific clinical diagnosis of PSP on the basis of currently available evidence. © 2017 International Parkinson and Movement Disorder Society.
- Published
- 2017
35. Characterization of gait variability in multiple system atrophy and Parkinson’s disease
- Author
-
Sidoroff, Victoria, Raccagni, Cecilia, Kaindlstorfer, Christine, Eschlboeck, Sabine, Fanciulli, Alessandra, Granata, Roberta, Eskofier, Björn, Seppi, Klaus, Poewe, Werner, Willeit, Johann, Kiechl, Stefan, Mahlknecht, Philipp, Stockner, Heike, Marini, Kathrin, Schorr, Oliver, Rungger, Gregorio, Klucken, Jochen, Wenning, Gregor, and Gaßner, Heiko
- Published
- 2021
- Full Text
- View/download PDF
36. Adapting to post-COVID19 research in Parkinson's disease: Lessons from a multinational experience
- Author
-
Tan, Eng-King, Albanese, Alberto, Chaudhuri, KRay, Lim, Shen-Yang, Oey, Nicodemus Edrick, Shan Chan, Christine Hui, Wu, Yun-Cheng, Jeon, Beomseok, Truong, Daniel, Poewe, Werner, Pal, Pramod Kumar, Tan, Louis, Opal, Puneet, Colosimo, Carlo, Jinnah, H.A., and Cardoso, Francisco
- Published
- 2021
- Full Text
- View/download PDF
37. Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement
- Author
-
Palma, Jose-Alberto, Vernetti, Patricio Millar, Perez, Miguel A., Krismer, Florian, Seppi, Klaus, Fanciulli, Alessandra, Singer, Wolfgang, Low, Phillip, Biaggioni, Italo, Norcliffe-Kaufmann, Lucy, Pellecchia, Maria Teresa, Martí, Maria José, Kim, Han-Joon, Merello, Marcelo, Stankovic, Iva, Poewe, Werner, Betensky, Rebecca, Wenning, Gregor, and Kaufmann, Horacio
- Published
- 2021
- Full Text
- View/download PDF
38. Early Screening for the Parkinson Variant of Multiple System Atrophy: A 6‐Item Score.
- Author
-
Fanciulli, Alessandra, Stankovic, Iva, Avraham, Omer, Jecmenica Lukic, Milica, Ezra, Adi, Leys, Fabian, Goebel, Georg, Krismer, Florian, Petrovic, Igor, Svetel, Marina, Seppi, Klaus, Kostic, Vladimir, Giladi, Nir, Poewe, Werner, Wenning, Gregor K., and Gurevich, Tanya
- Subjects
MULTIPLE system atrophy ,PARKINSON'S disease ,ORTHOSTATIC hypotension ,OVERACTIVE bladder ,SENSITIVITY & specificity (Statistics) - Abstract
Background: A 4‐item score based on ≥2 features out of orthostatic hypotension, overactive bladder, urinary retention and postural instability was previously shown to early distinguish the Parkinson‐variant of multiple system atrophy (MSA‐P) from Parkinson's disease (PD) with 78% sensitivity and 86% specificity. Objectives: To replicate and improve the 4‐item MSA‐P score. Methods: We retrospectively studied 161 patients with early parkinsonism [ie, ≤2 years disease duration or no postural instability, aged 64 (57; 68) years, 44% females] and a diagnosis of clinically established MSA‐P (n = 38) or PD (n = 123) after ≥24 months follow‐up. Results: The 4‐item MSA‐P score had a 92% sensitivity and 78% specificity for a final MSA‐P diagnosis. By including dopaminergic responsiveness and postural deformities into a 6‐item score (range: 0–6), reaching ≥3 points at early disease identified MSA‐P patients with 89% sensitivity and 98% specificity. Conclusions: The 6‐item MSA‐P score is a cost‐effective tool to pinpoint individuals with early‐stage MSA‐P. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers
- Author
-
Mangesius, Stephanie, Mariotto, Sara, Ferrari, Sergio, Pereverzyev, Sergiy, Jr., Lerchner, Hannes, Haider, Lukas, Gizewski, Elke R., Wenning, Gregor, Seppi, Klaus, Reindl, Markus, and Poewe, Werner
- Published
- 2020
- Full Text
- View/download PDF
40. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial
- Author
-
Volc, Dieter, Poewe, Werner, Kutzelnigg, Alexandra, Lührs, Petra, Thun-Hohenstein, Caroline, Schneeberger, Achim, Galabova, Gergana, Majbour, Nour, Vaikath, Nishant, El-Agnaf, Omar, Winter, Dorian, Mihailovska, Eva, Mairhofer, Andreas, Schwenke, Carsten, Staffler, Günther, and Medori, Rossella
- Published
- 2020
- Full Text
- View/download PDF
41. Diagnostic potential of automated tractography in progressive supranuclear palsy variants
- Author
-
Potrusil, Thomas, Krismer, Florian, Beliveau, Vincent, Seppi, Klaus, Müller, Christoph, Troger, Felix, Göbel, Georg, Steiger, Ruth, Gizewski, Elke R., Poewe, Werner, and Scherfler, Christoph
- Published
- 2020
- Full Text
- View/download PDF
42. Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study
- Author
-
Grosset, Donald G., Dhall, Rohit, Gurevich, Tanya, Kassubek, Jan, Poewe, Werner H., Rascol, Olivier, Rudzinska, Monika, Cormier, Jennifer, Sedkov, Alexander, and Oh, Charles
- Published
- 2020
- Full Text
- View/download PDF
43. A genome-wide association study in multiple system atrophy
- Author
-
Sailer, Anna, Scholz, Sonja W, Nalls, Michael A, Schulte, Claudia, Federoff, Monica, Price, T Ryan, Lees, Andrew, Ross, Owen A, Dickson, Dennis W, Mok, Kin, Mencacci, Niccolo E, Schottlaender, Lucia, Chelban, Viorica, Ling, Helen, O'Sullivan, Sean S, Wood, Nicholas W, Traynor, Bryan J, Ferrucci, Luigi, Federoff, Howard J, Mhyre, Timothy R, Morris, Huw R, Deuschl, Günther, Quinn, Niall, Widner, Hakan, Albanese, Alberto, Infante, Jon, Bhatia, Kailash P, Poewe, Werner, Oertel, Wolfgang, Höglinger, Günter U, Wüllner, Ullrich, Goldwurm, Stefano, Pellecchia, Maria Teresa, Ferreira, Joaquim, Tolosa, Eduardo, Bloem, Bastiaan R, Rascol, Olivier, Meissner, Wassilios G, Hardy, John A, Revesz, Tamas, Holton, Janice L, Gasser, Thomas, Wenning, Gregor K, Singleton, Andrew B, Houlden, Henry, Calandra-Buonaura, Giovanna, Capellari, Sabina, and Cortelli, Pietro
- Subjects
Biomedical and Clinical Sciences ,Neurosciences ,Clinical Sciences ,Human Genome ,Genetics ,2.1 Biological and endogenous factors ,Aetiology ,Alkyl and Aryl Transferases ,Brain ,Cohort Studies ,Europe ,Genetic Loci ,Genome-Wide Association Study ,Genotyping Techniques ,Humans ,Multiple System Atrophy ,Polymorphism ,Single Nucleotide ,RNA ,Messenger ,United States ,Whites ,alpha-Synuclein ,European Multiple System Atrophy Study Group and the UK Multiple System Atrophy Study Group ,White People ,Cognitive Sciences ,Neurology & Neurosurgery ,Clinical sciences - Abstract
ObjectiveTo identify genetic variants that play a role in the pathogenesis of multiple system atrophy (MSA), we undertook a genome-wide association study (GWAS).MethodsWe performed a GWAS with >5 million genotyped and imputed single nucleotide polymorphisms (SNPs) in 918 patients with MSA of European ancestry and 3,864 controls. MSA cases were collected from North American and European centers, one third of which were neuropathologically confirmed.ResultsWe found no significant loci after stringent multiple testing correction. A number of regions emerged as potentially interesting for follow-up at p < 1 × 10-6, including SNPs in the genes FBXO47, ELOVL7, EDN1, and MAPT. Contrary to previous reports, we found no association of the genes SNCA and COQ2 with MSA.ConclusionsWe present a GWAS in MSA. We have identified several potentially interesting gene loci, including the MAPT locus, whose significance will have to be evaluated in a larger sample set. Common genetic variation in SNCA and COQ2 does not seem to be associated with MSA. In the future, additional samples of well-characterized patients with MSA will need to be collected to perform a larger MSA GWAS, but this initial study forms the basis for these next steps.
- Published
- 2016
44. Progressive Brain Atrophy in Multiple System Atrophy: A Longitudinal, Multicenter, Magnetic Resonance Imaging Study
- Author
-
Krismer, Florian, primary, Péran, Patrice, additional, Beliveau, Vincent, additional, Seppi, Klaus, additional, Arribarat, Germain, additional, Pavy‐Le Traon, Anne, additional, Meissner, Wassilios G., additional, Foubert‐Samier, Alexandra, additional, Fabbri, Margherita, additional, Schocke, Michael M., additional, Gordon, Mark Forrest, additional, Wenning, Gregor K., additional, Poewe, Werner, additional, Rascol, Olivier, additional, and Scherfler, Christoph, additional
- Published
- 2023
- Full Text
- View/download PDF
45. Deep brain stimulation reduces (nocturnal) dyskinetic exacerbations in patients with ADCY5 mutation: a case series
- Author
-
de Almeida Marcelino, Ana Luísa, Mainka, Tina, Krause, Patricia, Poewe, Werner, Ganos, Christos, and Kühn, Andrea A.
- Published
- 2020
- Full Text
- View/download PDF
46. Parkinson disease and the immune system — associations, mechanisms and therapeutics
- Author
-
Tan, Eng-King, Chao, Yin-Xia, West, Andrew, Chan, Ling-Ling, Poewe, Werner, and Jankovic, Joseph
- Published
- 2020
- Full Text
- View/download PDF
47. No effect of age, gender and total intracranial volume on brainstem MR planimetric measurements
- Author
-
Mangesius, Stephanie, Hussl, Anna, Tagwercher, Susanne, Reiter, Eva, Müller, Christoph, Lenhart, Lukas, Krismer, Florian, Mahlknecht, Philipp, Schocke, Michael, Gizewski, Elke R., Poewe, Werner, and Seppi, Klaus
- Published
- 2020
- Full Text
- View/download PDF
48. MDS clinical diagnostic criteria for Parkinson's disease.
- Author
-
Postuma, Ronald B, Berg, Daniela, Stern, Matthew, Poewe, Werner, Olanow, C Warren, Oertel, Wolfgang, Obeso, José, Marek, Kenneth, Litvan, Irene, Lang, Anthony E, Halliday, Glenda, Goetz, Christopher G, Gasser, Thomas, Dubois, Bruno, Chan, Piu, Bloem, Bastiaan R, Adler, Charles H, and Deuschl, Günther
- Subjects
Humans ,Parkinson Disease ,Severity of Illness Index ,Neuropsychological Tests ,Reference Standards ,Societies ,Scientific ,Parkinson's disease ,absolute exclusion criteria ,clinical diagnostic criteria ,motor parkinsonism ,non-motor manifestations ,red flags ,supportive criteria ,Neurology & Neurosurgery ,Clinical Sciences ,Human Movement and Sports Sciences ,Cognitive Sciences - Abstract
This document presents the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease (PD). The Movement Disorder Society PD Criteria are intended for use in clinical research but also may be used to guide clinical diagnosis. The benchmark for these criteria is expert clinical diagnosis; the criteria aim to systematize the diagnostic process, to make it reproducible across centers and applicable by clinicians with less expertise in PD diagnosis. Although motor abnormalities remain central, increasing recognition has been given to nonmotor manifestations; these are incorporated into both the current criteria and particularly into separate criteria for prodromal PD. Similar to previous criteria, the Movement Disorder Society PD Criteria retain motor parkinsonism as the core feature of the disease, defined as bradykinesia plus rest tremor or rigidity. Explicit instructions for defining these cardinal features are included. After documentation of parkinsonism, determination of PD as the cause of parkinsonism relies on three categories of diagnostic features: absolute exclusion criteria (which rule out PD), red flags (which must be counterbalanced by additional supportive criteria to allow diagnosis of PD), and supportive criteria (positive features that increase confidence of the PD diagnosis). Two levels of certainty are delineated: clinically established PD (maximizing specificity at the expense of reduced sensitivity) and probable PD (which balances sensitivity and specificity). The Movement Disorder Society criteria retain elements proven valuable in previous criteria and omit aspects that are no longer justified, thereby encapsulating diagnosis according to current knowledge. As understanding of PD expands, the Movement Disorder Society criteria will need continuous revision to accommodate these advances.
- Published
- 2015
49. MDS research criteria for prodromal Parkinson's disease.
- Author
-
Berg, Daniela, Postuma, Ronald B, Adler, Charles H, Bloem, Bastiaan R, Chan, Piu, Dubois, Bruno, Gasser, Thomas, Goetz, Christopher G, Halliday, Glenda, Joseph, Lawrence, Lang, Anthony E, Liepelt-Scarfone, Inga, Litvan, Irene, Marek, Kenneth, Obeso, José, Oertel, Wolfgang, Olanow, C Warren, Poewe, Werner, Stern, Matthew, and Deuschl, Günther
- Subjects
Humans ,Parkinson Disease ,Severity of Illness Index ,Societies ,Scientific ,Prodromal Symptoms ,Parkinson's disease ,diagnosis ,prodromal ,Neurology & Neurosurgery ,Clinical Sciences ,Human Movement and Sports Sciences ,Cognitive Sciences - Abstract
This article describes research criteria and probability methodology for the diagnosis of prodromal PD. Prodromal disease refers to the stage wherein early symptoms or signs of PD neurodegeneration are present, but classic clinical diagnosis based on fully evolved motor parkinsonism is not yet possible. Given the lack of clear neuroprotective/disease-modifying therapy for prodromal PD, these criteria were developed for research purposes only. The criteria are based upon the likelihood of prodromal disease being present with probable prodromal PD defined as ≥80% certainty. Certainty estimates rely upon calculation of an individual's risk of having prodromal PD, using a Bayesian naïve classifier. In this methodology, a previous probability of prodromal disease is delineated based upon age. Then, the probability of prodromal PD is calculated by adding diagnostic information, expressed as likelihood ratios. This diagnostic information combines estimates of background risk (from environmental risk factors and genetic findings) and results of diagnostic marker testing. In order to be included, diagnostic markers had to have prospective evidence documenting ability to predict clinical PD. They include motor and nonmotor clinical symptoms, clinical signs, and ancillary diagnostic tests. These criteria represent a first step in the formal delineation of early stages of PD and will require constant updating as more information becomes available.
- Published
- 2015
50. POEWE, Werner: Innsbruck/Austria
- Author
-
Poewe, Werner, Schneider, Susanne A., editor, and Comella, Cynthia, editor
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.